Taiho, Cullinan report improved PFS in Phase III NSCLC trial

​

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported results from the Phase III REZILIENT3 trial, showing that zipalertinib combined with chemotherapy significantly improved PFS for patients with previously untreated, advanced NSCLC.

The post Taiho, Cullinan report improved PFS in Phase III NSCLC trial appeared first on Hospital Management.

 

Back to the Featured Stories
Taiho, Cullinan report improved PFS in Phase III NSCLC trial

Featured Stories

Hyperfine concludes Contrast PMR study enrolment for Swoop MRI system
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Eli Lilly and QurCan sign genetic medicine deal
BRAINBox and Prolight sign supply agreement for concussion tests
Taiho, Cullinan report improved PFS in Phase III NSCLC trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us